Repligen starts phase-2b trial of bipolar disorder drug
Monday, November 10, 2008 16:00 IST Waltham, Massachusetts
Repligen Corporation announced that the company has initiated a phase-2b clinical trial to evaluate the use of RG2417, an oral formulation of uridine, in patients with bipolar depression.
